Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6081
Revised: January 18, 2014
Accepted: February 26, 2014
Published online: May 28, 2014
Core tip: Pre-operative treatment of locally advanced rectal cancer is a challenging issue in gastrointestinal oncology. Integrating an antiangiogenic agent such as bevacizumab into neoadjuvant chemo-radiotherapy protocols is a promising approach. We review the different strategies currently under evaluation in order to complement bevacizumab within a multimodality approach for locally advanced rectal cancer patients.